文献速递贫血与红细胞疾病

早期起始去铁酮在输血依赖型β地中海贫血婴幼儿中的疗效与安全性:一项随机双盲安慰剂对照临床试验(START)中转铁蛋白铁穿梭的证据

Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
PubMed 文献 · Am J Hematol · 2023-07-04

START研究纳入64例近期诊断的β地中海贫血婴幼儿(血清铁蛋白200–600 μg/L),随机1:1接受去铁酮或安慰剂12个月。第12个月时去铁酮组66%患者血清铁蛋白仍低于阈值,安慰剂组为39%(p = .045);去铁酮组转铁蛋白饱和度更高且更快达到≥60%阈值;去铁酮耐受良好,未出现铁耗竭。

要点

  • 早期起始去铁酮可减少婴幼儿输血依赖型β地中海贫血的铁过载。
  • 去铁酮组66%患者第12个月血清铁蛋白仍低于阈值,安慰剂组39%。
  • 去铁酮耐受良好,未出现铁耗竭,两组生长与不良事件率无显著差异。

核心结论

  • 早期起始去铁酮耐受良好,未出现铁耗竭,并能有效减少输血依赖型β地中海贫血婴幼儿的铁过载。
  • 转铁蛋白饱和度结果首次提供去铁酮将铁穿梭至转铁蛋白的临床证据。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验(START),纳入64例近期诊断的β地中海贫血婴幼儿,血清铁蛋白200–600 μg/L。
  • 患者按1:1随机分配接受去铁酮或安慰剂治疗12个月,或直至达到血清铁蛋白阈值(连续两次访视≥1000 μg/L)。
  • 去铁酮起始剂量25 mg/kg/天,增至50 mg/kg/天;部分接受者根据铁水平剂量增至75 mg/kg/天。

主要发现

  • 基线时两组平均年龄(去铁酮组3.03岁 vs 安慰剂组2.63岁)、血清铁蛋白(去铁酮组513.8 μg/L vs 安慰剂组451.7 μg/L)和转铁蛋白饱和度(去铁酮组47.98% vs 安慰剂组43.43%)无显著差异。
  • 第12个月时两组生长或不良事件率无显著差异,去铁酮组未出现铁耗竭患者。
  • 第12个月时去铁酮组66%患者血清铁蛋白仍低于阈值,安慰剂组为39%(p = .045)。
  • 去铁酮组转铁蛋白饱和度水平更高,且更快达到≥60%转铁蛋白饱和度阈值。

关键数值与推荐

  • 主要终点为第12个月时达到血清铁蛋白阈值(连续两次访视≥1000 μg/L)的患者比例。
  • 去铁酮组66%患者第12个月时血清铁蛋白仍低于阈值,安慰剂组39%(p = .045)。
  • 去铁酮组转铁蛋白饱和度更高,达到≥60%转铁蛋白饱和度阈值更快。

临床怎么用

  • 作者结论认为早期起始去铁酮耐受良好、未出现铁耗竭,并能有效减少婴幼儿输血依赖型β地中海贫血的铁过载。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with transfusion-dependent thalassemia (TDT) require regular blood transfusions that, without iron-chelation therapy, lead to iron-overload toxicities. Current practice delays chelation therapy (late-start) until reaching iron overload (serum ferritin ≥1000 μg/L) to minimize risks of iron-depletion. Deferiprone's distinct pharmacological properties, including iron-shuttling to transferrin, may reduce risks of iron depletion during mild-to-moderate iron loads and iron overload/toxicity in children with TDT. The early-start deferiprone (START) study evaluated the efficacy/safety of early-start deferiprone in infants/young children with TDT. Sixty-four infants/children recently diagnosed with beta-thalassemia and serum ferritin (SF) between 200 and 600 μg/L were randomly assigned 1:1 to receive deferiprone or placebo for 12 months or until reaching SF-threshold (≥1000 μg/L at two consecutive visits). Deferiprone was initiated at 25 mg/kg/day and increased to 50 mg/kg/day; some recipients' dosages increased to 75 mg/kg/day based on iron levels. The primary endpoint was the proportion of patients ≥SF-threshold by month 12. Monthly transferrin saturation (TSAT) assessment evaluated iron-shuttling. At baseline, there was no significant difference in mean age (deferiprone: 3.03 years, placebo: 2.63 years), SF (deferiprone: 513.8 μg/L, placebo: 451.7 μg/L), or TSAT (deferiprone: 47.98%, placebo: 43.43%) between groups. At month 12, there was no significant difference in growth or adverse event (AE) rates between groups. No deferiprone-treated patients were iron-depleted. At month 12, 66% of patients receiving deferiprone remained below SF threshold versus 39% of placebo (p = .045). Deferiprone-treated patients showed higher TSAT levels and reached ≥60% TSAT threshold faster. Early-start deferiprone was well-tolerated, not associated with iron depletion, and efficacious in reducing iron overload in infants/children with TDT. TSAT results provide the first clinical evidence of deferiprone shuttling iron to transferrin.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Elalfy MS, Hamdy M, Adly A, et al. Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). Am J Hematol. 2023. PMID: 37401738. doi:10.1002/ajh.27010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。